NeuroScientific Biopharmaceuticals Ltd. news
NeuroScientific Biopharmaceuticals Chairman, Paul Rennie provides an investor update to discuss the recent rejection of the Company`s HREC submission.
Dr Alexandra Heaton, Director of Operations at NeuroScientific Biopharmaceuticals sat down with Gareth Quinn of Repulbic PR to discuss the recent announcements at the Gold Coast Investor Showcase Conference - June, 2021
NeuroScientific Biopharmaceuticals Director of Operations, Dr Alexandra Andrews provided an overview of the Company’s peptide-based drug for the treatment of neurodegenerative conditions and an update on the Company`s progress towards clinical trials.
Vice President of Clinical Development, Dougal Thring provided an overview of the Company’s peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need.
NeuroScientifc Biopharmaceuticals says the $5 million it`s seeking to raise will fast track the development of an Alzheimer`s treatment that the biotech reckons could be "one of the greatest drugs ever".